Ann Arbor-area residents have one last opportunity to join the movement to create a world with less cancer and more birthdays by participating in Cancer Prevention Study-3 (CPS-3), a historic study that has the potential to change the face of cancer for future generations.
About a quarter of women experience moderate to severe pain for many years after their treatment ends. In many cases, it's a type of pain that is challenging to treat, with few or no effective options.
Wolverines and Detroiters walk the runway Oct. 18 to support breast cancer research at the University of Michigan.
A microfluidic chip developed at the University of Michigan is among the best at capturing elusive circulating tumor cells from blood -- and it can support the cells' growth for further analysis.
The University of Michigan Health System has begun offering a new urine test called Mi-Prostate Score to improve on PSA screening for prostate cancer. The test incorporates three specific markers that could indicate cancer and studies have shown that the combination is far more accurate than PSA alone.
Recent studies have suggested that an informed patient will be less likely to choose a more-extensive treatment than what the doctor recommends but a recent study by University of Michigan Comprehensive Cancer Cetner researchers have found that's not necessarily the case.
University of Michigan Comprehensive Cancer Center researchers Maha Hussain, M.D., and Arul Chinnaiyan, M.D., Ph.D., received two of six grant awards from the Movember-Prostate Cancer Foundation Challenge.
A new study from researchers at the University of Michigan Comprehensive Cancer Center found that these cells, called myeloid derived suppressor cells, provide a niche where the cancer stem cells survive.
New laser-based tool could dramatically improve the accuracy of brain tumor surgery, researchers show
Imaging technique tells tumor tissue from normal tissue, could be used in operating room for real-time guidance of surgeryWritten by Kara Gavin; contact via email or at 734-764-2220.
Xofigo, a newly approved treatment for advanced prostate cancer, delivers a powerful punch of radiation directly to tumor cells that have invaded the bone.